ABOUT US Mission and Objectives Message from the Chairman Message from the Secretary General Who Are We? Board of Directors Our Members Inspection Board Committees Pharmacovigilance Committee Intellectual Property Rights Committee GCP Committee Reimbursement Committee GPP Committee OTC (Non-Prescription Drugs) Committee PR Committee Regulatory Affairs Committee Anti-Counterfeiting Committee Charter Name of the Association Head Office Mission and Activities of the Association Membership Terms of Joining and Terminating Bodies of the Association General Assembly Board of Directors Inspection Board Internal Audit Secretary General Acquisition of Property Revenues and Expenditures of the Assoc. Dissolution of the Association Records of the Association Charter Amendments Absence of Ruling Applicable Language Founders of the Association Code of Promotion Position Documents SECTORIAL DATA Announcements of Moh & Legislation Frequently Asked Questions NEW DRUGS AND R&D What does it mean to be researcher? What is an “Original” drug? Implementations (Original & Generic) Patent Protection Data Exclusivity PRESS ROOM Press Announcement Press Releases News Insider AİFD Activities Reflections in the Press RESEARCHES AND PUBLICATIONS AIFD ACADEMY About AİFD Academy AİFD Academy Final Declaration Scientific Advisory Board AİFD Academy E-Bulletin Membership TR EN     Home Page » Detail Page 01.07.2009 AİFD: Close Collaboration And Harsh Penalties Key To Combating Counterfeit Drugs A meeting was held in Istanbul by the Association of Research-Based Pharmaceutical Companies (AİFD) to discuss the latest developments in the world and in Turkey in the fight against counterfeit drugs. With the introduction of a Drug Tracking System, which would mark the beginning of a new era in the fight against counterfeit drugs in Turkey, a meeting was held in Istanbul to discuss all aspects of the issue. Foreign and local experts, who participated in the meeting held by the Association of Research-Based Pharmaceutical Companies (AİFD) which gathers 39 innovative drug companies under its roof, considered the latest developments. AİFD Secretary General and Chief Operating Officer Alp Sevindik and AİFD’s Anti-Counterfeit Committee Chairperson Ahmet Kavuşturan were among the participants. During the meeting, Julian Harris, an expert from International Policy Network, gave a presentation of his report, titled “Keeping it Real: Combating the Spread of Fake Drugs”, and Robert Bate, an expert on health policy and counterfeit drugs from the American Enterprise Institute, gave an account of health risks posed by counterfeit drugs globally, and particularly in poor countries. Please click to see pdf format of this document.  You shall have ADOBE READER installed on your system to read the documents/files attached. Please click to download the program. All News » All Press Bulletin » MEMBER LOGIN INSIDER AİFD Right strategies will lead Turkey to a bright future SEARCH IN SITE DID YOU KNOW THAT…? IMPORTANT TERMS SITE MAP USEFUL LINKS CONFIDENTIALITY-TERMS OF USE CONTACT Abbott • Actelion • Alcon • Alexion İlaç Ticaret Ltd. Şti. • Amgen • Astellas • AstraZeneca • Bayer Türk Kimya San. Ltd. Şti. • Boehringer İngelheim • Bristol-Myers Squibb • Celgene • Chiesi • Daiichi-Sankyo • Eczacıbaşı-Baxter • Ferring • Fresenius Kabi • Fresenius Medical Care • Genzyme Sağlık Hizmetleri ve Tedavi Ürünleri Tic.Ltd.Şti. • Gilead Sciences İlaç.Tic. Ltd. Şti. • GlaxoSmithKline • IBSA İlaç San. ve Tic. Ltd. Şti. • Intendis • İ.E.Ulagay • Johnson&Johnson • Lilly • Lundbeck • Merck Serono • MSD Türkiye • Nestle • Novartis Sağlık Ürünleri • Novo Nordisk • Nutricia Klinik Beslenme • Pfizer İlaçları Ltd. Şti • Roche Müstahzarları San. A.Ş. • Sanofi-aventis • Servier • U.C.B. Pharma • Wyeth İlaçları Limited Şirketi • AİFD is a member of IFPMA – International Federation of Pharmaceutical Manufacturers and Associations and EFPIA (European Federation of Pharmaceutical Industries and Associations).     © Association of Research-Based Pharmaceutical Companies Last Update : 03.09.2010